

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ALNY | NASDAQ | USD | Real-time | |
ALNY | BIVA | MXN | Delayed | |
ALNY | TradeGate | EUR | Delayed | |
A1LN34 | B3 | BRL | Delayed |
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Yvonne L. Greenstreet | 60 | 2016 | CEO & Director |
Rachel Meyers | - | - | Member of Scientific Advisory Board |
Olivier Brandicourt | 67 | 2020 | Independent Director |
Dennis Arthur Ausiello | 78 | 2012 | Member of the Scientific Advisory Board & Independent Director |
Daniel J. Rader | - | - | Member of Scientific Advisory Board |
Michael W. Bonney | 65 | 2014 | Non-Independent Director |
Nancy J. Brown | - | 2015 | Member of Scientific Advisory Board |
Margaret A. Hamburg | 68 | 2019 | Independent Director |
Markus Stoffel | - | - | Member of Scientific Advisory Board |
Priya S. Kishnani | - | 2020 | Member of the Scientific Advisory Board |
Charles Elliott Sigal | 71 | 2022 | Independent Director |
Carolyn R. Bertozzi | 58 | 2023 | Member of Scientific Advisory Board & Independent Director |
Colleen Foley Reitan | 64 | 2018 | Independent Director |
David E. I. Pyott | 72 | 2015 | Independent Director |
Peter N. Kellogg | 69 | 2023 | Independent Director |
Amy W. Schulman | 64 | 2014 | Independent Chair of the Board |
Muthiah Manoharan | 72 | 2003 | Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board |
Akshay K. Vaishnaw | 62 | 2006 | Chief Innovation Officer & Member of the Scientific Advisory Board |
Phillip A. Sharp | 80 | 2002 | Co-Founder, Member of the Scientific Advisory Board & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review